Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Clinical Cancer Research

• Publication date

  2003-07-01

• Fields of study

  Medicine

• Identifiers
  PMID 12855610
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The role of bisphosphonates in breast cancer.

  2003cited by this paper
• The case for a new national program for the development of cancer therapeutics.

  2001cited by this paper
• American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel.

  2000cited by this paper
• Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group.

  1999cited by this paper
• Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group.

  1998cited by this paper
• Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group.

  1998cited by this paper
• Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review.

  1998cited by this paper
• Bone metastases: improving the therapeutic index.

  1994cited by this paper
• Inhibition of bone resorption by bisphosphonates: Interactions between bisphosphonates, osteoclasts, and bone

  1991cited by this paper
• Metastases in carcinoma. Analysis of 1000 autopsied cases

  1950cited by this paper

• Infectious/Inflammatory Oral Diseases and Medication-Related Osteonecrosis of the Jaw (MRONJ).

  2026cites this paper
• Resumption of bone-modifying agents in relapsed multiple myeloma does not improve outcomes: A real-world analysis.

  2026cites this paper
• Efficacy of Bone-Modifying Agents in Preventing Vertebral Complications of Multiple Myeloma: A Systematic Review and Meta-Analysis.

  2025cites this paper
• Handbook of Statistics in Clinical Oncology

  2025cites this paper
• Polygenic Risk Score as a Predictor of Bone Fracture or Osteoporosis in Prostate Cancer Patients Receiving Androgen Deprivation Therapy

  2025cites this paper
• Prognostic indicators in medication-related osteonecrosis of the jaw: A systematic review and meta-analysis

  2025cites this paper
• Mild antiresorptive activity of an anti-vascular endothelial growth factor A antibody and sunitinib in a rat model of bone resorption

  2025cites this paper
• Review of Bone Metastasis in Gynecologic Malignancies: Evaluation and Treatment

  2025cites this paper
• Systematic Review-Based Treatment Algorithm for the Multidisciplinary Treatment of Lung Cancer Bone Metastases

  2024cites this paper
• Nanotheranostics in Breast Cancer Bone Metastasis: Advanced Research Progress and Future Perspectives

  2024cites this paper
• Mechanism exploration of Zoledronic acid combined with PD-1 in the treatment of hepatocellular carcinoma

  2024cites this paper
• Development of novel imidazole-2-one/-2-thione heterocyclic derivatives as antimicrobial and antiproliferative agents and evaluation through biological studies and molecular modeling simulations

  2024cites this paper
• Molecular landscape of prostate cancer bone metastasis.

  2024cites this paper
• Pharmaceutical treatment of bone loss: From animal models and drug development to future treatment strategies.

  2023cites this paper
• Depletion of macrophages deteriorates bisphosphonate-related osteonecrosis of the jaw-like lesions in mice.

  2023cites this paper
• Conventional androgen deprivation therapy is associated with an increased risk of fracture in advanced prostate cancer, a nationwide population-based study

  2023cites this paper
• Factors affecting local control of bone metastases from radioresistant tumors treated with palliative external beam radiotherapy

  2023cites this paper
• Prognostic factors in metastatic prostate cancer

  2023cites this paper
• A variability in response of osteoclasts to zoledronic acid is mediated by smoking-associated modification in the DNA methylome

  2023cites this paper
• Associations Among Physical Activity, Skeletal Related Events, and Patient Reported Outcomes in Patients with Bone Metastases.

  2022cites this paper
• Repurposed and investigational disease-modifying drugs in osteoarthritis (DMOADs)

  2022cites this paper
• New Imidazole-Based N-Phenylbenzamide Derivatives as Potential Anticancer Agents: Key Computational Insights

  2022cites this paper
• Skeletal-Related Events After Surgery With or Without Radiotherapy for Bone Metastases to Weight-Bearing Bones

  2022cites this paper
• Zoledronic Acid Deteriorates Soft and Hard Tissue Healing of Murine Tooth Extraction Sockets in a Dose-Dependent Manner

  2021cites this paper
• All bone metastases are not created equal: Revisiting treatment resistance in renal cell carcinoma

  2021cites this paper
• A Multi-institutional, Retrospective Analysis of Patients with Metastatic Renal Cell Carcinoma to Bone Treated with Combination Ipilimumab and Nivolumab

  2021cites this paper
• Acute Tubular Necrosis Caused by Zoledronic Acid Infusion in a Patient With Osteoporosis.

  2021cites this paper
• Bone Targeting Agents in Patients with Metastatic Prostate Cancer: State of the Art

  2021cites this paper
• Recent Advances in Nanomedicine for the Diagnosis and Treatment of Prostate Cancer Bone Metastasis

  2021cites this paper
• Retrospective Evaluation of Acute Kidney Injury After Zoledronic Acid Administration to Dogs With Malignant Osteolysis

  2021cites this paper
• Sarcomas of Bone and Soft Tissues in Children and Adolescents

  2021cites this paper
• Frequency and Clinicopathological Features of Distant Metastasis of Bladder Cancer: A SEER-Based Study

  2021cites this paper
• Gene expression analysis of fresh extraction wounds prior to onset of bisphosphonate-related osteonecrosis of the jaw-like lesions in mice: A preliminary animal study.

  2021cites this paper
• Racial Disparities in Intravenous Bisphosphonate Use Among Older Patients With Multiple Myeloma Enrolled in Medicare.

  2021influential citation
• Zoledronic Acid Is Not Equally Potent on Osteoclasts Generated From Different Individuals

  2020cites this paper
• Strategies for New Agent Development in Pediatric Sarcomas

  2020cites this paper
• Prognosis of Medication-Related Osteonecrosis of the Jaws in Metastatic Prostate Cancer Patients.

  2020cites this paper
• Zoledronate and SPIO dual-targeting nanoparticles loaded with ICG for photothermal therapy of breast cancer tibial metastasis

  2020cites this paper
• A Case of Rare Cutaneous Metastasis from Advanced Pancreatic Cancer

  2020cites this paper
• Prognosis of medication-related osteonecrosis of the jaws in cancer patients using antiresorptive agent zoledronic acid.

  2020cites this paper
• Bone‐Specific Drugs and Osteonecrosis of Sites Other Than the Jaw: A Nationwide Cohort Study

  2020cites this paper
• Radiation therapy combined with bone-modifying agents ameliorates local control of osteolytic bone metastases in breast cancer

  2020cites this paper
• Low-dose zoledronate for the treatment of bone metastasis secondary to prostate cancer

  2019cites this paper
• Anti-Tumor Effects of Low Dose Zoledronate on Lung Cancer-Induced Spine Metastasis

  2019cites this paper
• Humanized bone facilitates prostate cancer metastasis and recapitulates therapeutic effects of zoledronic acid in vivo

  2019cites this paper
• Does Bone-targeted Therapy Benefit Patients with Metastatic Renal Cell Carcinoma?

  2019cites this paper
• The effects of metastatic lesion on the structural determinants of bone: Current clinical and experimental approaches.

  2019cites this paper
• Ras inhibition by zoledronic acid effectively sensitizes cervical cancer to chemotherapy.

  2019cites this paper
• Bone Health Issues in Patients with Prostate Cancer: An Evidence-Based Review

  2019cites this paper
• Zoledronic acid for the treatment of prostate cancer

  2019cites this paper
• Incidence of skeletal-related events in patients with breast or prostate cancer-induced bone metastasis or multiple myeloma: A 12-year longitudinal nationwide healthcare database study.

  2019cites this paper
• Incidence of skeletal-related events in advanced and metastatic prostate cancer patients treated with androgen deprivation therapy in a low- and middle-income country

  2019cites this paper
• Induction of multiple myeloma bone marrow stromal cell apoptosis by inhibiting extracellular vesicle miR-10a secretion.

  2019cites this paper
• Pain Assessment after Short Course versus Long Course Palliative Radiation of Painful Bony Metastasis

  2018cites this paper
• Antigen-Presenting Cell Characteristics of Human γδ T Lymphocytes in Chronic Myeloid Leukemia

  2018cites this paper
• Prognostic Factors in Patients with Metastatic Breast Cancer with Bone‐Only Metastases

  2018influential citation
• Revisiting the role of bone‐modifying agents in the management of metastatic prostate cancer

  2018cites this paper
• EXPLORING THE EFFECT OF CHRONIC INFLAMMATION ON RESPONSE TO IMMUNE CHECKPOINT INHIBITORS IN CANCER

  2018cites this paper
• Evaluation du contrôle local des oligo-métastases osseuses traitées par cyberknife entre 2007 et 2015 à L’Institut de Cancérologie de Lorraine

  2018cites this paper
• Practical consensus recommendaton for adjuvant bone-modifying agents in breast cancer

  2018cites this paper
• Advances in treatment of metastatic breast cancer with bone metastasis.

  2018cites this paper
• Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology.

  2018cites this paper
• 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid‐Induced Osteoporosis

  2017cites this paper
• Posibles efectos adversos oculares de los bifosfonatos. Reporte de 2 casos

  2017cites this paper
• Histological and Immunohistochemical (ANXA1) Analysis of Bisphosphonate (Zoledronate) Effect on Submandibular and Parotid Glands in Neonatal Rats

  2017cites this paper
• Zoledronic acid increases the prevalence of medication-related osteonecrosis of the jaw in a dose dependent manner in rice rats (Oryzomys palustris) with localized periodontitis

  2017cites this paper
• American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis

  2017cites this paper
• Evidence of novel miR-34a-based therapeutic approaches for multiple myeloma treatment

  2017cites this paper
• Epidemiologic Analysis Along the Mevalonate Pathway Reveals Improved Cancer Survival in Patients Who Receive Statins Alone and in Combination With Bisphosphonates.

  2017cites this paper
• Treatment of Medication-Related Osteonecrosis of the Jaw and its Impact on a Patient’s Quality of Life: A Single-Center, 10-Year Experience from Southern Italy

  2017cites this paper
• Role of zoledronic acid in oncolytic virotherapy: Promotion of antitumor effect and prevention of bone destruction

  2017cites this paper
• Possible ocular adverse effects attributable to bisphosphonate therapy: Two case reports

  2017cites this paper
• Studies on tissue protective cytokines in remyelination and regenerative medicine

  2016cites this paper
• Rheumatoid Arthritis Exacerbates the Severity of Osteonecrosis of the Jaws (ONJ) in Mice. A Randomized, Prospective, Controlled Animal Study

  2016cites this paper
• Measurement of Ototoxicity Following Intracochlear Bisphosphonate Delivery

  2016cites this paper
• Molecular mechanisms linking geranylgeranyl diphosphate synthase to cell survival and proliferation

  2016cites this paper
• Bone metastases, clinical trials II: zoledronic acid and denosumab in the prevention of bone metastases

  2015cites this paper
• Short-Term Safety of Zoledronic Acid in Young Patients With Bone Disorders: An Extensive Institutional Experience.

  2015cites this paper
• Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy

  2015cites this paper
• Complications of Bisphosphonate Therapy in Multiple Myeloma: A Review

  2015influential citation
• Analysis of denosumab on skeletal-related events in patients with advanced breast cancer.

  2015cites this paper
• Depleting Glycine and Sarcosine in Prostate Cancer Cells as a New Treatment for Advanced Prostate Cancer

  2015cites this paper
• The bisphosphonate zoledronic acid effectively targets lung cancer cells by inhibition of protein prenylation.

  2015cites this paper
• THE ROLE OF TURMERIC AS AN ADJUVANT THERAPEUTIC FOR OSTEOLYTIC BREAST CANCER BONE METASTASES

  2015cites this paper
• How I do it: managing bone health in patients with prostate cancer.

  2014cites this paper
• Plant-derived anticancer agents: a promising treatment for bone metastasis.

  2014cites this paper
• Survival Benefit of Zoledronic Acid in Postmenopausal Breast Cancer Patients Receiving Aromatase Inhibitors

  2014cites this paper
• RANKL抑制剂地诺塞麦所致颌骨坏死 Denosumab, a RANKL Inhibitor, Induced Osteonecrosis of the Jaw

  2014cites this paper
• A New Approach to Cancer Therapy: The Tumor Microenvironment as Target

  2014cites this paper
• The Tumor Microenvironment as Target for New Cancer Therapies

  2014cites this paper
• NCCN Guidelines Version 1.2015 Panel Members Non-Small Cell Lung Cancer

  2014cites this paper
• Hyaluronic Acid Conjugates as Vectors for the Active Targeting of Drugs, Genes and Nanocomposites in Cancer Treatment

  2014cites this paper
• Interferon-γ and celecoxib inhibit lung-tumor growth through modulating M2/M1 macrophage ratio in the tumor microenvironment

  2014cites this paper
• Therapeutic modulation of prostate cancer metastasis.

  2014cites this paper
• Acrometastasis from a Pancreatic Primary Adenocarcinoma: A First Report in the Literature

  2014cites this paper
• Recent advances in bone-targeted therapies of metastatic prostate cancer.

  2014cites this paper
• Denosumab, a RANKL Inhibitor, Induced Osteonecrosis of the Jaw *

  2014cites this paper
• The role of tumour–stromal interactions in modifying drug response: challenges and opportunities

  2013cites this paper
• Genes, molecules and patients—Emerging topics to guide clinical pain research

  2013cites this paper
• Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features—An exploratory analysis of placebo-controlled trials

  2013cites this paper